Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cue Biopharma Inc (CUE)

Cue Biopharma Inc (CUE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 23,779
  • Shares Outstanding, K 78,738
  • Annual Sales, $ 9,290 K
  • Annual Income, $ -40,670 K
  • EBIT $ -38 M
  • EBITDA $ -38 M
  • 60-Month Beta 1.47
  • Price/Sales 3.67
  • Price/Cash Flow N/A
  • Price/Book 1.61
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.46
  • Most Recent Earnings $-0.07 on 11/12/25
  • Next Earnings Date 03/30/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 362.47% (-191.95%)
  • Historical Volatility 162.64%
  • IV Percentile 61%
  • IV Rank 35.79%
  • IV High 931.67% on 10/14/25
  • IV Low 45.25% on 11/20/25
  • Expected Move (DTE 32) 0.0595 (19.70%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 5
  • Volume Avg (30-Day) 34
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 1,791
  • Open Int (30-Day) 1,635
  • Expected Range 0.2425 to 0.3615

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.10
  • Number of Estimates 1
  • High Estimate -0.10
  • Low Estimate -0.10
  • Prior Year -0.13
  • Growth Rate Est. (year over year) +23.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2302 +31.19%
on 12/24/25
0.4369 -30.88%
on 01/05/26
-0.1080 (-26.34%)
since 12/16/25
3-Month
0.2302 +31.19%
on 12/24/25
0.8500 -64.47%
on 11/04/25
-0.4881 (-61.78%)
since 10/16/25
52-Week
0.2302 +31.19%
on 12/24/25
1.5400 -80.39%
on 02/18/25
-0.9780 (-76.41%)
since 01/16/25

Most Recent Stories

More News
Cue Biopharma Announces Pricing of $10 Million Public Offering

BOSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate...

CUE : 0.3020 (+9.03%)
Cue Biopharma Announces Proposed Public Offering

BOSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...

CUE : 0.3020 (+9.03%)
Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Announced strategic collaboration and license agreement with ImmunoScape to develop breakthrough cell therapy approach for solid tumors – Company is entitled to receive upfront payments totaling $15M...

CUE : 0.3020 (+9.03%)
Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors

Exclusive collaboration and license agreement focuses on advancing novel T cell therapy “Seed-and-Boost” approach exploiting the mechanism of the CUE-100 series of Immuno-STATs® Novel therapeutic...

CUE : 0.3020 (+9.03%)
Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates

Usman Azam, M.D., is appointed President and Chief Executive Officer of Cue Biopharma, effective September 29, 2025 Daniel Passeri, Chief Executive Officer of Cue Biopharma, transitions to Strategic...

CUE : 0.3020 (+9.03%)
Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference

BOSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...

CUE : 0.3020 (+9.03%)
Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme

First patient dosed with CUE-102 for recurrent glioblastoma multiforme (rGBM) at Dana-Farber Cancer Institute (DFCI) BOSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.  (Nasdaq: CUE),...

CUE : 0.3020 (+9.03%)
Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Received FDA feedback on Pre-IND Briefing Document reinforcing Company’s intention to advance investigational new drug (IND) submission for CUE-401 to address unmet need in the treatment of autoimmune...

CUE : 0.3020 (+9.03%)
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds

USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc.

ALLO : 1.6300 (+1.24%)
ONCY : 1.0100 (+3.80%)
CUE : 0.3020 (+9.03%)
ONC.TO : 1.42 (+2.16%)
CATX : 2.33 (-6.05%)
VSTM : 6.68 (+1.21%)
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds

/CNW/ -- USA News Group News Commentary – Cancer diagnoses are climbing fastest among younger women, sparking alarm that looming cuts to U.S. research budgets...

ALLO : 1.6300 (+1.24%)
ONCY : 1.0100 (+3.80%)
CUE : 0.3020 (+9.03%)
ONC.TO : 1.42 (+2.16%)
CATX : 2.33 (-6.05%)
VSTM : 6.68 (+1.21%)

Business Summary

Cue Biopharma, Inc. is an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. Cue Biopharma, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 0.3388
2nd Resistance Point 0.3227
1st Resistance Point 0.3124
Last Price 0.3020
1st Support Level 0.2860
2nd Support Level 0.2699
3rd Support Level 0.2596

See More

52-Week High 1.5400
Fibonacci 61.8% 1.0397
Fibonacci 50% 0.8851
Fibonacci 38.2% 0.7305
Last Price 0.3020
52-Week Low 0.2302

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar